INTRODUCTION: Abuse of inhalants and solvents is a significant public health problem. There is no specific treatment for inhalant withdrawal. OBJECTIVE: To study the effect of baclofen in treating craving and withdrawal symptoms in patients with inhalant dependence. CASE REPORTS: Case studies of 3 young male patients with DSM-IV diagnoses of inhalant dependence treated in an inpatient setting with baclofen are presented. All patients had nonspecific withdrawal symptoms in the form of irritability, insomnia, and craving. Baclofen was given in doses up to 50 mg/day and was continued throughout the period of hospitalization. DISCUSSION: All patients reported significant reduction in withdrawal symptoms within 48 hours of treatment and were free of symptoms for the duration of their hospital stay. One patient continued the medication as an outpatient and has remained abstinent to date. Baclofen was well tolerated by all patients. Our results suggest that baclofen may be an effective treatment modality in this patient population. These effects are possibly due to the agonistic action of baclofen at gamma-aminobutyric acid B receptors in the ventral tegmental area.
INTRODUCTION: Abuse of inhalants and solvents is a significant public health problem. There is no specific treatment for inhalant withdrawal. OBJECTIVE: To study the effect of baclofen in treating craving and withdrawal symptoms in patients with inhalant dependence. CASE REPORTS: Case studies of 3 young male patients with DSM-IV diagnoses of inhalant dependence treated in an inpatient setting with baclofen are presented. All patients had nonspecific withdrawal symptoms in the form of irritability, insomnia, and craving. Baclofen was given in doses up to 50 mg/day and was continued throughout the period of hospitalization. DISCUSSION: All patients reported significant reduction in withdrawal symptoms within 48 hours of treatment and were free of symptoms for the duration of their hospital stay. One patient continued the medication as an outpatient and has remained abstinent to date. Baclofen was well tolerated by all patients. Our results suggest that baclofen may be an effective treatment modality in this patient population. These effects are possibly due to the agonistic action of baclofen at gamma-aminobutyric acid B receptors in the ventral tegmental area.
Authors: Steven Shoptaw; Xiaowei Yang; Erin J Rotheram-Fuller; Ya-Ching M Hsieh; Prudencia C Kintaudi; V C Charuvastra; Walter Ling Journal: J Clin Psychiatry Date: 2003-12 Impact factor: 4.384
Authors: Marisa Roberto; Samuel G Madamba; Scott D Moore; Melanie K Tallent; George R Siggins Journal: Proc Natl Acad Sci U S A Date: 2003-02-03 Impact factor: 11.205
Authors: Giovanni Addolorato; Fabio Caputo; Esmeralda Capristo; Marco Domenicali; Mauro Bernardi; Luigi Janiri; Roberta Agabio; Giancarlo Colombo; Gian Luigi Gessa; Giovanni Gasbarrini Journal: Alcohol Alcohol Date: 2002 Sep-Oct Impact factor: 2.826
Authors: Giovanni Addolorato; Lorenzo Leggio; Ludovico Abenavoli; Giosue DeLorenzi; Antonio Parente; Fabio Caputo; Luigi Janiri; Esmeralda Capristo; Gian Ludovico Rapaccini; Giovanni Gasbarrini Journal: Clin Neuropharmacol Date: 2003 Sep-Oct Impact factor: 1.592